novartis_microsoft_ai_still006_4k

Novartis

3 October 2019Big PharmaRory O'Neill

Novartis and Microsoft to collaborate on AI in medicine

Novartis has teamed with Microsoft to launch a new artificial intelligence (AI) innovation lab, which it says has the potential to “transform” and “reimagine” medicine.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSPN 19: AI ‘explosion’ and drug costs in Canada

17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

More on this story

LSPN 19: AI ‘explosion’ and drug costs in Canada

17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

More on this story

LSPN 19: AI ‘explosion’ and drug costs in Canada

17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

More features

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?

Broad Institute wins appeal to restore CRISPR patent in Europe

BMS faces fresh lawsuit over alleged cancer drug monopoly

WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations

Boies Schiller Flexner adds three-strong litigation team